Clinical Trial Detail

NCT ID NCT02852655
Title A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma multiforme

gliosarcoma

malignant glioma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.